Iovance Biotherapeutics (IOVA) Stock Forecast, Price Target & Predictions
IOVA Stock Forecast
Iovance Biotherapeutics stock forecast is as follows: an average price target of $21.57 (represents a 108.61% upside from IOVA’s last price of $10.34) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
IOVA Price Target
The average price target for Iovance Biotherapeutics (IOVA) is $21.57 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $6.00. This represents a potential 108.61% upside from IOVA's last price of $10.34.
IOVA Analyst Ratings
According to 9 Wall Street analysts, Iovance Biotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for IOVA stock is 0 'Strong Buy' (0.00%), 7 'Buy' (77.78%), 2 'Hold' (22.22%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Iovance Biotherapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2024 | Benjamin Burnett | Stifel Nicolaus | $23.00 | $7.94 | 189.67% | 122.44% |
| Aug 09, 2024 | Colleen Kusy | Robert W. Baird | $24.00 | $7.94 | 202.27% | 132.11% |
| Jul 29, 2024 | Joseph Catanzaro | Piper Sandler | $10.00 | $9.25 | 8.11% | -3.29% |
| Jun 20, 2024 | Reni Benjamin | JMP Securities | $23.00 | $8.00 | 187.50% | 122.44% |
| May 31, 2024 | Benjamin Burnett | Stifel Nicolaus | $28.00 | $8.88 | 215.32% | 170.79% |
| Mar 14, 2024 | Joseph Catanzaro | Piper Sandler | $19.00 | $14.21 | 33.71% | 83.75% |
| Dec 08, 2022 | Madhu Kumar | Goldman Sachs | $6.00 | $7.17 | -16.32% | -41.97% |
| Nov 20, 2022 | Joseph Catanzaro | Piper Sandler | $11.00 | $6.62 | 66.16% | 6.38% |
| Aug 23, 2022 | Michael Ulz | Robert W. Baird | $25.00 | $11.50 | 117.39% | 141.78% |
| Jul 01, 2022 | - | Goldman Sachs | $18.00 | $11.04 | 63.04% | 74.08% |
The latest Iovance Biotherapeutics stock forecast, released on Aug 09, 2024 by Benjamin Burnett from Stifel Nicolaus, set a price target of $23.00, which represents a 189.67% increase from the stock price at the time of the forecast ($7.94), and a 122.44% increase from IOVA last price ($10.34).
Iovance Biotherapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 6 |
| Avg Price Target | - | $20.00 | $21.17 |
| Last Closing Price | $10.34 | $10.34 | $10.34 |
| Upside/Downside | -100.00% | 93.42% | 104.74% |
In the current month, the average price target of Iovance Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Iovance Biotherapeutics's last price of $10.34. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 12, 2024 | Piper Sandler | Market Outperform | Market Outperform | Hold |
| Jul 29, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
| Jul 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 20, 2024 | JMP Securities | Outperform | Outperform | Hold |
| May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Feb 20, 2024 | Chardan Capital | Buy | Buy | Hold |
| Dec 08, 2022 | Goldman Sachs | Buy | Neutral | Downgrade |
| Nov 20, 2022 | Piper Sandler | Neutral | Neutral | Hold |
Iovance Biotherapeutics's last stock rating was published by Cowen & Co. on Aug 14, 2024. The company gave IOVA a "Buy" rating, the same as its previous rate.
Iovance Biotherapeutics Financial Forecast
Iovance Biotherapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $469.00K | $238.00K | - |
| Avg Forecast | $31.11M | $31.11M | $31.11M | $31.11M | $134.33M | $123.58M | $108.26M | $96.26M | $77.02M | $53.77M | $24.59M | $2.03M | $1.44M | $4.50M | $3.91M | $222.22K |
| High Forecast | $31.72M | $31.72M | $31.72M | $31.72M | $136.97M | $126.01M | $110.39M | $98.16M | $78.54M | $54.53M | $25.08M | $2.07M | $2.31M | $4.59M | $3.99M | $226.60K |
| Low Forecast | $30.65M | $30.65M | $30.65M | $30.65M | $132.35M | $121.76M | $106.67M | $94.84M | $75.89M | $53.32M | $24.23M | $2.00M | $564.81K | $4.43M | $3.85M | $218.96K |
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.10% | 0.06% | - |
Iovance Biotherapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $1.44M, with a low forecast of $564.81K, and a high forecast of $2.31M. IOVA's average Quarter revenue forecast represents a 207.21% increase compared to the company's last Quarter revenue of $469.00K (Sep 23).
Iovance Biotherapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-118.36M | $-110.09M | $-110.86M |
| Avg Forecast | $18.66M | $18.66M | $18.66M | $18.66M | $80.60M | $74.15M | $64.95M | $57.75M | $46.21M | $32.26M | $14.76M | $1.22M | $864.50K | $2.70M | $2.35M | $133.33K |
| High Forecast | $19.03M | $19.03M | $19.03M | $19.03M | $82.18M | $75.61M | $66.23M | $58.89M | $47.12M | $32.72M | $15.05M | $1.24M | $1.38M | $2.75M | $2.39M | $135.96K |
| Low Forecast | $18.39M | $18.39M | $18.39M | $18.39M | $79.41M | $73.06M | $64.00M | $56.91M | $45.53M | $31.99M | $14.54M | $1.20M | $338.88K | $2.66M | $2.31M | $131.37K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -43.84% | -46.94% | -831.42% |
undefined analysts predict IOVA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Iovance Biotherapeutics's previous annual EBITDA (undefined) of $NaN.
Iovance Biotherapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-113.76M | $-106.53M | $-103.88M |
| Avg Forecast | $26.49M | $18.17M | $10.77M | $2.34M | $-40.81M | $-45.35M | $-53.25M | $-64.52M | $-76.76M | $-85.16M | $-100.67M | $-120.86M | $-122.69M | $-129.48M | $-141.91M | $-161.49M |
| High Forecast | $27.17M | $18.64M | $11.04M | $2.40M | $-40.03M | $-44.48M | $-52.23M | $-63.29M | $-75.29M | $-68.68M | $-98.75M | $-118.55M | $-111.54M | $-127.01M | $-139.20M | $-158.41M |
| Low Forecast | $25.98M | $17.82M | $10.56M | $2.29M | $-41.86M | $-46.51M | $-54.61M | $-66.17M | $-78.72M | $-96.15M | $-103.25M | $-123.96M | $-131.06M | $-132.80M | $-145.54M | $-165.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.88% | 0.75% | 0.64% |
Iovance Biotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IOVA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Iovance Biotherapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $26.96M | $21.93M | $28.12M |
| Avg Forecast | $467.24M | $467.24M | $467.24M | $467.24M | $2.02B | $1.86B | $1.63B | $1.45B | $1.16B | $807.65M | $369.44M | $30.48M | $21.64M | $67.59M | $58.72M | $3.34M |
| High Forecast | $476.45M | $476.45M | $476.45M | $476.45M | $2.06B | $1.89B | $1.66B | $1.47B | $1.18B | $819.14M | $376.72M | $31.08M | $34.63M | $68.93M | $59.88M | $3.40M |
| Low Forecast | $460.38M | $460.38M | $460.38M | $460.38M | $1.99B | $1.83B | $1.60B | $1.42B | $1.14B | $800.85M | $364.01M | $30.03M | $8.48M | $66.60M | $57.86M | $3.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.40% | 0.37% | 8.42% |
Iovance Biotherapeutics's average Quarter SG&A projection for Dec 23 is $21.64M, based on 8 Wall Street analysts, with a range of $8.48M to $34.63M. The forecast indicates a -19.73% fall compared to IOVA last annual SG&A of $26.96M (Sep 23).
Iovance Biotherapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.46 | $-0.47 | $-0.49 |
| Avg Forecast | $0.09 | $0.06 | $0.04 | $0.01 | $-0.14 | $-0.16 | $-0.19 | $-0.23 | $-0.27 | $-0.30 | $-0.35 | $-0.42 | $-0.43 | $-0.45 | $-0.50 | $-0.57 |
| High Forecast | $0.10 | $0.07 | $0.04 | $0.01 | $-0.14 | $-0.16 | $-0.18 | $-0.22 | $-0.26 | $-0.24 | $-0.35 | $-0.42 | $-0.39 | $-0.45 | $-0.49 | $-0.56 |
| Low Forecast | $0.09 | $0.06 | $0.04 | $0.01 | $-0.15 | $-0.16 | $-0.19 | $-0.23 | $-0.28 | $-0.34 | $-0.36 | $-0.44 | $-0.46 | $-0.47 | $-0.51 | $-0.58 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 0.94% | 0.86% |
According to undefined Wall Street analysts, Iovance Biotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IOVA previous annual EPS of $NaN (undefined).
Iovance Biotherapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| CVAC | CureVac | $3.44 | $29.00 | 743.02% | Buy |
| IOVA | Iovance Biotherapeutics | $10.34 | $21.57 | 108.61% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| SRPT | Sarepta Therapeutics | $124.65 | $169.93 | 36.33% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| PTCT | PTC Therapeutics | $33.99 | $44.33 | 30.42% | Hold |
| KRYS | Krystal Biotech | $201.58 | $191.00 | -5.25% | Buy |
IOVA Forecast FAQ
Is Iovance Biotherapeutics a good buy?
Yes, according to 9 Wall Street analysts, Iovance Biotherapeutics (IOVA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 77.78% of IOVA's total ratings.
What is IOVA's price target?
Iovance Biotherapeutics (IOVA) average price target is $21.57 with a range of $6 to $40, implying a 108.61% from its last price of $10.34. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Iovance Biotherapeutics stock go up soon?
According to Wall Street analysts' prediction for IOVA stock, the company can go up by 108.61% (from the last price of $10.34 to the average price target of $21.57), up by 286.85% based on the highest stock price target, and down by -41.97% based on the lowest stock price target.
Can Iovance Biotherapeutics stock reach $20?
IOVA's average twelve months analyst stock price target of $21.57 supports the claim that Iovance Biotherapeutics can reach $20 in the near future.
What are Iovance Biotherapeutics's analysts' financial forecasts?
Iovance Biotherapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $462.42M (high $471.53M, low $455.63M), average EBITDA is $277.45M (high $282.92M, low $273.38M), average net income is $-204M (high $-200M, low $-209M), average SG&A $6.95B (high $7.08B, low $6.84B), and average EPS is $-0.716 (high $-0.702, low $-0.734). IOVA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $124.42M (high $126.88M, low $122.6M), average EBITDA is $74.65M (high $76.13M, low $73.56M), average net income is $57.76M (high $59.24M, low $56.66M), average SG&A $1.87B (high $1.91B, low $1.84B), and average EPS is $0.203 (high $0.208, low $0.199).
Did the IOVA's actual financial results beat the analysts' financial forecasts?
Based on Iovance Biotherapeutics's last annual report (Dec 2023), the company's revenue was $1.19M, which missed the average analysts forecast of $10.07M by -88.20%. Apple's EBITDA was $-461M, missing the average prediction of $6.04M by -7721.00%. The company's net income was $-444M, missing the average estimation of $-556M by -20.08%. Apple's SG&A was $106.92M, missing the average forecast of $151.29M by -29.33%. Lastly, the company's EPS was $-1.89, missing the average prediction of $-1.951 by -3.11%. In terms of the last quarterly report (Sep 2023), Iovance Biotherapeutics's revenue was $469K, missing the average analysts' forecast of $4.5M by -89.58%. The company's EBITDA was $-118M, missing the average prediction of $2.7M by -4483.74%. Iovance Biotherapeutics's net income was $-114M, missing the average estimation of $-129M by -12.14%. The company's SG&A was $26.96M, missing the average forecast of $67.59M by -60.11%. Lastly, the company's EPS was $-0.46, beating the average prediction of $-0.455 by 1.19%